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Purpose. To analyse the capacity of whole-blood NGAL (wbNGAL) to stratify AKI in critically ill patients with and without sepsis.
Methods. Whole-blood NGAL was measured with a point-of-care device at admission and 48 hours later in patients admitted to a
general ICU. Patients were classified by the AKIN and KDIGO classifications at admission and 24 and 48 hours. We performed an
ROC curve analysis. wbNGAL values at admission were compared in patients with sepsis and septic shock. Results. The study
included 100 consecutively admitted patients (40 female) with mean age 59 1 ± 17 8 years. Thirty-three patients presented AKI
at admission, and 10 more developed it in the next 48 h. Eighteen patients had AKI stage 3, 14 of them at admission. Nine
patients required renal replacement therapy. According to KDIGO at admission, wbNGAL values were 78 μg/L (60-187) in stage
0 (n = 67), 263μg/L (89-314) in stage 1 (n = 8), 484μg/L (333-708) in stage 2 (n = 11), and 623μg/L (231-911) in stage 3 (n = 14),
p = 0 0001 for trend. Ten patients did not complete 48 hours of study: 6 of 10 were discharged (initial wbNGAL 130 μg/L (60-
514)) and 4 died (773 μg/L (311-1010)). The AUROC curve of wbNGAL to predict AKI was 0.838 (95% confidence interval
0.76-0.92, p = 0 0001), with optimal cut-off value of 178 μg/L (sensitivity 76.7%, specificity 78.9%, p < 0 0001). At admission,
twenty-nine patients had sepsis, of whom 20 were in septic shock. wbNGAL concentrations were 81 μg/L (60-187) in patients
without sepsis, 481 (247-687) in those with sepsis, and 623.5 μg/L (361-798) in the subgroup of septic shock (p < 0 0001).
Conclusions. Whole-blood NGAL concentration at ICU admission was a good stratifier of AKI in critically ill patients. However,
wbNGAL concentrations were higher in septic patients irrespective of AKI occurrence.
1. Introduction
Acute kidney injury (AKI) is a disease often diagnosed in
intensive care unit (ICU) patients. AKI incidence can be as
high as 24% depending on its definition [1]. ICU-related
AKI is associated with an in-hospital mortality that can reach
60% [2, 3]. Therefore, early AKI detection is crucial to pre-
vent or stop the natural course of renal dysfunction and
improve its morbi-mortality. Serum creatinine is the gold
standard biomarker in all AKI definitions [4–6]. However,
creatinine is a late biomarker for AKI, as values peak after
24-48 hours of renal injury. Hence, several biomarkers have
been proposed for early AKI detection [7, 8].
Neutrophil gelatinase-associated lipocalin (NGAL) is a
glycoprotein first isolated from specific granules of human
leukocytes [9]. NGAL was found elevated in bacterial infec-
tions when compared to viral infections [10]. NGAL exists
as a monomeric form of 25 kDa, a homodimer linked by a
disulphide bridge of 45 kDa and a heterodimer with matrix
metalloproteinase-9 (MMP-9, gelatinase) with an intermo-
lecular disulphide bridge of 135 kDa [11]. NGAL is also
formed in other cells apart from leukocytes. In response to
several injuries, NGAL is expressed in kidney, hepatic, or epi-
thelial cells [11–13]. In the kidneys, NGAL is freely filtered by
the glomerulus and reabsorbed in the proximal tubule [14].
After a tubular injury, NGAL is overexpressed in the diseased
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endothelium [15–17]. In this setting, tubular reabsorption is
reduced, and blood and urine NGAL concentrations
increase. In AKI, NGAL increase is observed 24-48 hours
earlier than plasma creatinine peak [18, 19]. However, the
specificity of NGAL to detect AKI could be limited by overex-
pression in other tissues [20]. This could be relevant in criti-
cally ill patients, in whom sepsis could promote NGAL
release from tissues other than renal epithelium [21, 22].
NGAL has been described as a predictor of AKI and the need
of renal replacement therapies (RRT) in patients admitted to
general intensive care units (ICU) [21–24]. However, as a
systematic review by Hjortrup et al. [24] pointed out, the
NGAL role is not fully understood: literature shows that
NGAL might predict AKI with a wide range AUROC, from
0.54 to 0.98. The aims of this study were (1) to evaluate the
capacity of whole-blood NGAL at ICU admission to predict
AKI development and (2) to analyse the effect of sepsis on
its predictive capacity.
2. Methods
2.1. Patients. The study protocol was approved by the Ethic
Committee Board at Hospital de la Santa Creu i Sant Pau
(Barcelona, Spain). We obtained informed consent from par-
ticipants or their guardians. The study prospectively included
100 patients consecutively admitted during 8 months (June
2010-February 2011) in a general ICU. Inclusion criteria
were age over 18 years old and the expected ICU stay of at
least 48 hours. Patients were excluded if they had already
been admitted in the hospital for more than 24 hours, had
any degree of preexisting chronic kidney disease, or were
not expected to survive for at least 24 hours due to a nonre-
versible clinical condition. Physicians attending patients were
blinded to NGAL results throughout the study.
2.2. Clinical and Laboratory Data Collection. Clinical data
included admission diagnosis, demographics, ICU severity
scores, haemodynamic parameters, and urine output.
Patients were initially classified following the AKIN defini-
tion [5] and KDIGO [6] definition for AKI. Both definitions
were based on serum creatinine and urine output obtained
since admission to 6 hours later, at 24 and 48 hours of admis-
sion. Baseline serum creatinine was taken from patients’ pre-
admission records whenever possible and used to estimate
eGFR before ICU admission using the Cockcroft–Gault for-
mula. According to standard criteria [25], patients were also
classified as having sepsis and septic shock.
NGAL was measured at admission and 24 and 48 hours
in EDTA-anticoagulated whole-blood using the Triage®
NGAL Test (Alere Diagnostics, formerly Inverness Medical
Innovations). All samples were analysed in the same batch
to avoid between-batch variability.
2.3. Statistical Analysis. SPSS® version 18 (SPSS Inc.,
Chicago, IL) was used. Variables with normal distribution
are reported as mean ± standard deviation and were com-
pared with Student’s t-test or one-way analysis of variance.
Variables with non-Gaussian distribution are reported as
median and interquartile range (IQR) and were compared
with the Mann–Whitney U or Kruskal-Wallis tests. Categor-
ical data are reported as percentage and were compared by
the chi-square test or Fisher exact test. Reporting of results
followed the STARD (Standards for Reporting Diagnostic
Accuracy Studies) statement. Whole-blood NGAL predictive
values were evaluated by receiver operating characteristic
(ROC) curve analysis. We defined an area under the ROC
(AUROC) curve of 0.60-0.69 as poor, 0.70-0.79 as fair,
0.80-0.89 as good, and 0.90-1.00 as excellent in terms of pre-
dictive value. A p < 0 05 was considered significant.
3. Results
3.1. Clinical Characteristics. We recruited 100 consecutive
patients fulfilling the admission criteria (Figure 1). Ten of
them did not complete the 48 h follow-up due to discharge
(6 cases) or death (4 cases). Mean age was 59 1 ± 17 8 years.
60% of cases were male. The causes of ICU admission were
medical 54% (respiratory 26%, cardiovascular 7%), postsur-
gical care 39% (gastrointestinal 21%, neurosurgery 12%),
and miscellaneous 7%. At ICU admission, twenty-nine were
septic, and twenty of them had septic shock. ICU length of
stay was 10 3 ± 9 6 days, and ICU mortality was 22%.
3.2. Whole-Blood NGAL and AKI. Forty-three patients pre-
sented AKI, 33 at admission (8 stage 1, 11 stage 2, and 14
stage 3) and 10 more within 48 h of the ICU stay; 4 of the
latest group of 10 developed renal failure (stage 3). Nine
patients required renal replacement therapies. wbNGAL
values were 78μg/L (IQR 60-187μg/L) in non-AKI patients
and 263μg/L (IQR 89-314μg/L), 484μg/L (IQR 333-
708μg/L), and 623μg/L (IQR 231-911μg/L) in those with
stage 1, stage 2, and stage 3, respectively (p = 0 0001 for
trend) (Figure 2). Four of 33 patients with AKI at admis-
sion were diagnosed of AKI solely because of urine output
criterion (one patient had stage 1, one patient had stage 2,
and two patients had stage 3); 10 of 33 patients were diag-
nosed of AKI based on changes in sCr, and the remaining
19 patients were diagnosed based in both sCr and drop of
urine output. The incidence and severity of AKI were the
same when AKIN classification was applied within the first
48 h.
In the group of 6 patients discharged before 24 h, admis-
sion wbNGAL and plasma creatinine were of 130μg/L (IQR
60-514) and 78μmol/L (IQR 54-123), respectively; whereas
in the 4 patients who died, wbNGAL was of 773μg/L (IQR
311-1010) and plasma creatinine 165μmol/L (IQR 59-577).
We did not find statistical differences in wbNGAL or serum
creatinine between subgroups of patients who were dis-
charged or passed away.
Whole-blood NGAL values were predictive of AKI both
at admission and within 48h of the ICU stay (Supplemental
Table 1). The area under the ROC curve (AUROC) of
wbNGAL for AKI prediction within 48 hours of ICU
admission was 0.838 (95% confidence interval (CI) 0.760-
0.917, p = 0 0001). The wbNGAL optimal cut-off for AKI
within 48 h of ICU admission was 178μg/L, with sensitivity
of 76.7% and specificity of 78.9% (Figure 3). The AUROC
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Figure 2: Boxplot comparing whole-blood NGAL (wbNGAL)
concentrations (μg/L) and KDIGO score at admission. Boxplots
indicate the median and 25th and 75th percentiles. Whiskers
indicate the 5th and 95th percentiles. Statistical significance (p)
comparing wbNGAL (μg/L) with KDIGO categories is given at the
bottom of the figure.
Potentially eligible participants
n = 305
205 patients were excluded
because of previous hospital admission
for more than 24 h,
chronic kidney disease,
nonreversible cause of ICU admission,
and lack of consent.Eligible participants
n = 100
wbNGAL test at admission
n = 100
Test-negative
wbNGAL < 178 휇g/L
n = 67
Test-positive
wbNGAL ≥ 178 휇g/L
n = 33
Inconclusive n = 0
Reference standard:
AKIN at admission
No AKI n = 0
Stage 1 n = 8
Stage 2 n = 11
Stage 3 n = 14
Inconclusive n = 0
Reference standard:
AKIN at admission
No AKI n = 67
AKI = 0
















Sensivity 76.7%; specificity 78.9%
AUROC: 0.838 (0.760-0.917; p < 0.0001)
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Figure 3: ROC curve for whole-blood NGAL value at ICU
admission to predict AKI. Diagnostic and overall accuracies given
with sensitivity, specificity, and 95% confidence interval compared
with gold standard KDIGO classification.
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of ICU admission was 0.904 (95% CI 0.841-0.967, p = 0 0001).
There were no statistical differences between wbNGAL and
plasma creatinine AUROC.
Forty-five patients had wbNGAL > 178 μg/L. They were
more likely to be older, have higher SOFA at admission,
have higher incidence of AKI development, stage 3, sepsis,
or septic shock, and have requirement of vasopressor
drugs and renal replacement therapies during the ICU stay
(Table 1). Six of eighteen patients without AKI at admission
butwbNGAL > 178 μg/L developed AKI within the next 48 h.
Accordingly, wbNGAL identified at admission extra 14.6% of
AKI patients not diagnosed by the serum creatinine criterion.
3.3. Whole-Blood NGAL and Sepsis.wbNGAL concentrations
were 81μg/L (IQR 60-187) and 481μg/L (IQR 247-681) in 71
patients without sepsis and 29 patients with sepsis, respec-
tively (p < 0 0001) (Figure 4). wbNGAL was 623.5μg/L
(IQR 361-798) in those 20 of 29 septic patients who also
had shock. The incidence of AKI in sepsis and septic shock
was 28.6% and 65%, respectively.
Serial measurement of wbNGAL did not improve
AKI prediction in septic patients compared to nonseptic
patients (data not shown). In nonseptic patients, AKI con-
centrations appeared dependent on AKI status: 62μg/L
(IQR 60-99) in non-AKI and 297μg/L (IQR 123-502)
in AKI patients, p < 0 0001. However, when comparing
wbNGAL in septic patients with (632μg/L (IQR 344-1060))
or without (414μg/L (IQR 214-552)) AKI, there was no
Table 1: Clinical characteristics of the study patients depending on the cut-off obtained for AKI prediction.
<178 μg/L ≥178 μg/L p value
n 55 45 —
Age (years) 54 9 ± 18 5 64 ± 15 5 0.009
Male 37 (67) 23 (51) 0.075
Characteristics at ICU admission
SAPS II 37 8 ± 14 3 43 15 ± 15 5 0.095
APACHE II 15 ± 6 9 18 ± 8 2 0.059
SOFA 5 2 ± 2 7 7 7 ± 3 6 <0.0001
AKI admission (%) 6 (10.9) 27 (15.6) <0.0001
KDIGO stage 3 at admission (%) 2 (3.6) 12 (26.7) 0.001
RRT admission (%) 2 (3.6) 3 (6.7) 0.400
Creatinine clearance (mL/min) 109 ± 58 57 ± 52 <0.0001
Cockcroft–Gault 104 ± 47 58 ± 38 <0.0001
Characteristics during ICU stay
Mechanical ventilation (%) 46 (82) 36 (80) 0.410
Vasopressor requirement (%) 6 (11) 22 (49) <0.0001
ICU length of stay (days) 11 1 ± 9 3 9 4 ± 10 0.360
ICU mortality (%) 10 (18.2) 12 (26.7) 0.210
Sepsis 3 (5.5) 26 (57.8) 0.007
Septic shock 2 (3.6) 18 (40) <0.0001
AKI development (%) 2 (3.6) 6 (13.3) 0.070
KDIGO stage 3 development (%) 2 (3.6) 16 (35.6) <0.0001
RRT after admission (%) 0 (0) 4 (8.9) 0.038
RRT total (%) 2 (3.6) 7 (15.6) 0.040
Values expressed as either % per column or mean ± standard deviation. p: value of statistical significance. SAPS II: Simplified Acute Physiology Score II;
APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment score; AKI: acute kidney injury; KDIGO:






























Figure 4: Whole-blood NGAL concentrations (μg/L) according to
the presence of sepsis. Boxplots indicate the median and 25th and
75th percentiles of wbNGAL in ng/L. Whiskers indicate the 5th
and 95th percentiles. Statistical significance (p). Patients without
sepsis n = 71; patients with sepsis n = 29.
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statistical difference (p = 0 46). Septic patients with and with-
out AKI presented higher wbNGAL than those with the same
renal status without sepsis (p < 0 0001 for both compari-
sons). wbNGAL values in septic non-AKI patients were
undistinguishable of those of nonseptic AKI patients (p =
0 676). Nine of the 11 non-AKI patients with wbNGAL higher
than the cut-off >178μg/L presented sepsis (Figure 5). In
our study, there were 20 patients with septic shock: 3 had
no AKI (median wbNGAL of 481μg/L, IQR 142-481μg/L),
2 had stage 1 (251, IQR 234-269μg/L), 4 had stage 2 (562,
IQR 421-681μg/L), and 11 had stage 3 (685, IQR 526-
1130μg/L).
4. Discussion
Themain finding of our study is that admission wbNGAL is a
good stratifier of AKI within 48 hours of ICU admission in a
heterogeneous group of critically ill patients (AUROC 0.838
(95% CI 0.760-0.917, p < 0 0001)). The cut-off value higher
than 178μg/L defines a group of patients with higher severity
and higher probability of developing AKI. However, NGAL
concentrations were affected by sepsis status irrespective of
the AKI presence (p = 0 46). Thus, NGAL measures are not
useful to evaluate kidney function in patients with sepsis.
Some studies suggested that NGAL in blood or urine
could be a useful biomarker of AKI [26]. Most of those initial
studies were done in patients after cardiac surgery [7, 27], in
context of contrast-induced nephropathy [28], kidney
transplantation [18], or chronic kidney disease [29]. Fewer
studies were done in general critically ill population, both
paediatric [30, 31] and adult patients [19, 21, 32, 33]. There
is still debate whether NGAL is a good predictor of AKI in
general ICU patients [24]. Our AUROC of wbNGAL is sig-
nificantly higher than that found by Parikh et al. [18] in the
postoperative care in cardiac surgery and by Haase et al.
[22] in a paediatric critically ill population. In our study,
wbNGAL stratified AKI severity, showing increasing concen-
trations with an increased KDIGO stage from median values
of 71μg/L in stage 1 and 186μg/L in stage 2 to 381μg/L in
stage 3 (Figure 2). This increasing pattern in line with the
severity of AKI has also been described by other investigators
in paediatric and adult patients [24, 25]. Although wbNGAL
concentrations in non-AKI patients are similar to those
found by Singer et al. [25], AKI severity categories were lower
in our study. In view of our results, we would suggest clini-
cians to consider wbNGAL as a complementary tool in
patients at AKI risk or receiving nephrotoxic drugs. Despite
NGAL’s promising results in general ICU population, the
AKIKI [34], ELAIN [35], and the most recent IDEAL-ICU
[36] trials showed that wbNGAL combined with KDIGO
staging did not improve the timing of renal replacement ther-
apies or patient’s prognosis.
In our cohort, the AUROC curve of wbNGAL for AKI
prediction showed an optimal cut-off value of 178μg/L.
Our cut-off is close to the ones described in other studies,
around 150μg/L [22, 27, 37]. In critically ill patients, the
AKI+
















p = 0.017 p < 0.0001 
p = 0.46
Figure 5: Distribution of admission whole-blood NGAL (μg/L) values at ICU admission depending on AKI and sepsis. AKI+ vs. AKI- and
sepsis+ vs. sepsis- represents the presence or absence of either AKI or sepsis upon admission, respectively. Values show median and
percentiles 25-75. p represents the statistical intragroup differences. wbNGAL values given in μg/L. &Statistical difference between
subgroups of nonseptic AKI vs. septic non-AKI patients (p = 0 676). &&Statistical difference between subgroups of nonseptic non-AKI vs.
septic and AKI patients (p < 0 0001). AKI: acute kidney injury.
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exact time when acute tubular damage occurs is often
unknown. The differences in AUROC described in literature
could also be explained by their study designs. Unlike our
study, those set up in cardiac surgery or radiocontrast admin-
istration had an exact time of a potential onset of renal injury.
We found significant differences in admission wbNGAL
between the groups of patients with AKI and those without.
We also identified a subgroup of patients who presented high
levels of wbNGAL with no increase of creatinine. This sub-
group could be considered false positives or, in our opinion,
a subgroup of patients who may represent subclinical AKI
[22]. Patients with stage 1 showed relatively low wbNGAL
concentrations within the group of patients with AKI. This
finding could be attributable to treated reversible causes of
AKI, like hypovolemia or hypotension. Nickolas et al. [38]
described low levels of urine NGAL in patients with prerenal
azotaemia. Those patients inadequately resuscitated after a
prerenal azotaemia had increasing urinary NGAL concentra-
tions. Similar to our study, this is a clinically relevant finding.
Timely treatment of patients with subclinical AKI or stage 1
could avoid AKI progression to failure and tubular damage.
NGAL is a protein upregulated after a tubular injury
[39]. However, it can also be produced by other organs like
the liver or lung [7] or in different inflammatory situations
[40]. In our study, the serial measurement of wbNGAL did
not improve AKI prediction in septic patients compared to
nonseptic patients. No statistical differences were found
between ROC curves obtained at admission and 48 h later;
both ROC curves produced very similar cut-offs (Supple-
mental Table 1). These results concur with those from
Bagshaw et al. [41], which showed that peak plasma NGAL
did not perform better to predict AKI in septic than in
nonseptic patients. This is clinically relevant because single
sampling at admission decreases costs, and it is easier to
implement in daily routine.
wbNGAL values were higher in patients with sepsis
and much higher in those with septic shock. These data
strongly suggest that wbNGAL not only is a good predictor
of AKI but also can be considered a good severity score in
patients with inflammatory status. Although Mishra et al.
[27] showed that plasma NGAL was independent of inflam-
matory markers like C-reactive protein, Zappitelli et al. [31]
reported that plasma and urine NGAL concentrations at
ICU admission were higher in patients in which AKI was
due to sepsis than in those in which it was due to nonseptic
causes. Like in our study, these authors found that serial
NGAL measurement did not add predictive power to NGAL
concentrations at admission. Other articles also suggested
that the inflammatory status [24] or septic shock could
influence wbNGAL concentrations [22], and this could be
found regardless of the presence of AKI [42]. Kim et al.
[43] described that wbNGAL was significantly higher in sep-
tic patients with AKI regardless of their levels of procalcito-
nin. In our subgroup of 20 patients with septic shock, 3 of
them had no AKI, 2 stage 1, 4 stage 2, and 11 stage 3, with
median wbNGAL of 481μg/L, 251μg/L, 562μg/L, and
685μg/L, respectively. These data favour the hypothesis that
inflammatory status could increase the level of wbNGAL and
could be misleadingly interpreted as a tubular damage when
it has not yet occurred. In these cases, urinary NGAL, which
is not submitted to the influence of inflammatory mediators,
could have better performance in AKI prediction. Besides,
differentiation of monomeric and dimeric plasma NGAL iso-
forms could be crucial to recognise the NGAL concentration
secondary to renal damage or inflammation [44]. Our data
also suggest that NGAL may be a biomarker of illness sever-
ity. In an article by Shapiro et al. [8], NGAL was a good pre-
dictor of septic shock in a panel of multiple biomarkers and
correlated with survival. Wang et al. also described that high
wbNGAL independently predicted mortality and multiple
organ dysfunction syndrome in sepsis and septic shock [45].
On the other hand, a study set up in the emergency
department by Wang et al. [46] suggested that combined
NGAL and TIMP-1 (tissue inhibitor of matrix metallopro-
teinases-1, a cell cycle arrest biomarker for AKI) was use-
ful for the diagnosis and risk stratification of patients with
AKI, including those who also presented with sepsis.
Although cell cycle arrest (CCA) biomarkers are still under
evaluation in different clinical settings, their sole predictive
power and risk stratification appears to be higher than that
exhibited by NGAL. Since CCA biomarkers were presented
in Sapphire study [47], there has been an increasing num-
ber of studies in paediatric [48] and adult critical care pop-
ulations, with clinical implementation in rapid response
teams [49] and KDIGO care bundles [50, 51]. Besides,
unlike NGAL, CCA biomarkers are not determined by
sepsis [52, 53].
Our study has some limitations. First of all, the sample
size was small, and the study was performed in a single cen-
tre. Secondly, we recruited a cohort that might not represent
an average ICU population. We aimed to study the AKI inci-
dence in a population with ideally normal baseline renal
function. AKI is a common complication of many nonrenal
hospitalisations [54–56]. We purposefully excluded patients
with a background of chronic disease and/or admitted in
the hospital for more than 24 hours prior to ICU admission.
However, this is also the main strength of our study, because
our unique cohort of patients were not under the effect of
intrahospital risk factors for AKI that could have acted as
confounding variables. Finally, the point-of-care test used
to analyse wbNGAL was not able to differentiate between
NGAL isoforms, which could have helped to explain the role
of inflammation in wbNGAL concentrations.
5. Conclusions
Our study showed that whole-blood NGAL concentrations
at ICU admission stratified AKI in adult critically ill patients.
Nonetheless, wbNGAL concentrations increased by sepsis
status irrespective of AKI occurrence. Thus, NGAL mea-
sures should be avoided to evaluate kidney function in
patients with sepsis.
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